Observational studyPloS one2026
A prospective observational study of plasma concentrations and safety of combined intravenous lidocaine and epidural ropivacaine in laparotomy surgery.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05368753 (Evaluation of Plasma Concentrations of Intravenous Lidocaine and Epidural Ropivacaine When Used in Combination in Major Abdominal Surgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Plasma Concentrations of Intravenous Lidocaine and Epidural Ropivacaine When Used in Combination in Major Abdominal Surgery
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous lidocaine (IVL), an alternative to epidural analgesia (EA) for laparotomies, has demonstrated anti-inflammatory and anti-hyperalgesic effects. However, its combination with EA raises concerns about systemic toxicity. This study aimed to assess the safety of this combination in patients undergoing laparotomy. We conducted a prospective observational study at Amiens University Hospital in France, involving adult patients scheduled for laparotomies. Intravenous lidocaine was administered at induction as a 1.5 mg/kg bolus (ideal body weight), followed by a continuous infusion of 2 mg/kg/h maintained until the end of surgery. An epidural catheter was inserted before surgery, prior to induction of general anesthesia, no local anesthetic was administered intraoperatively. Epidural analgesia was initiated at the end of surgery with a 5 mg bolus of ropivacaine, followed by a continuous infusion. The primary outcome was the occurrence of lidocaine and ropivacaine plasma concentrations outside established safety ranges. Lidocaine plasma concentrations were measured 30 minutes after bolus (LP1), at the end of surgery (LP2), and two hours after discontinuation of the infusion (LP3). Ropivacaine concentrations were measured two hours (RP1) and 24 hours after initiation of epidural infusion (RP2). The secondary endpoint the assessment of cardiac and neurological toxicity within 48 hours post-surgery. Fifty patients were included from March 2022 to March 2024. One patient exceeded the lidocaine threshold (LP2), and another exceeded the ropivacaine threshold (RP2). LP1 was 1.8 [1.5-2.4] µg/ml, LP2 was 2.1 [1.6-2.4] µg/ml, and LP3 was 1.2 [0.8-1.7] µg/ml. Ropivacaine plasma concentration was 126 [87-211] µg/L at RP1, and 785 [524-1318] µg/L at RP2. No cardiac or neurological adverse events were observed. The combination of EA and IVL appeared to be safe for major abdominal surgery. Clinical trials Number NCT05368753. EudraCT Number: 2021-005508-37.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.